Difference between revisions of "Ubiquitin-conjugating enzyme E2 L3"
(→Protein Function) |
(→Reference) |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 9: | Line 9: | ||
UBE2L3 expressed in 226 organ(s), highest expression level in C1 segment of cervical spinal cord. <br/> | UBE2L3 expressed in 226 organ(s), highest expression level in C1 segment of cervical spinal cord. <br/> | ||
The reaction of UBE2L3: <br/> | The reaction of UBE2L3: <br/> | ||
| − | S-ubiquitinyl-[E1 | + | <div align="center">S-ubiquitinyl-[E1]-L-cysteine + [E2]-L-cysteine = [E1]-L-cysteine + S-ubiquitinyl-[E2]-L-cysteine.</div> |
[[File:571-function-UB.jpg|center|1000px]] | [[File:571-function-UB.jpg|center|1000px]] | ||
<div align="center">PMID: 27002218</div> | <div align="center">PMID: 27002218</div> | ||
| Line 46: | Line 46: | ||
# Strickson S, Campbell D G, Emmerich C H, et al. '''The anti-inflammatory drug BAY 11-7082 suppresses the MyD88-dependent signalling network by targeting the ubiquitin system[J].''' Biochemical Journal, 2013, 451(3): 427-437. [https://www.ncbi.nlm.nih.gov/pubmed/?term=23441730 23441730]<br/> | # Strickson S, Campbell D G, Emmerich C H, et al. '''The anti-inflammatory drug BAY 11-7082 suppresses the MyD88-dependent signalling network by targeting the ubiquitin system[J].''' Biochemical Journal, 2013, 451(3): 427-437. [https://www.ncbi.nlm.nih.gov/pubmed/?term=23441730 23441730]<br/> | ||
| − | [[Category: | + | [[Category:Targets]] |
| − | [[Category: | + | [[Category:Homo sapiens]] |
| − | [[Category: | + | [[Category:Ubiquitinase/Deubiquitinase]] |
| − | [[Category: | + | [[Category:Post-translational Modification]] |
| − | [[Category: | + | [[Category:Ubiquitin-conjugating enzyme family]] |
| − | [[Category: | + | [[Category:Ubiquitin mediated proteolysis]] |
| − | [[Category: | + | [[Category:Parkinson disease]] |
Latest revision as of 23:02, 19 August 2019
| Basic Information | |
|---|---|
| Short Name | UbcH7, UBE2L3, Ubiquitin-protein ligase L3 |
| UNP ID | P68036 |
| Organism | Homo sapiens |
| Cys Site | Cys86 |
| Family/Domain | Ubiquitin-conjugating enzyme family |
| Known Ligand | Ligand list |
| Function Type |
Ubiquitinase/Deubiquitinase, Post-translational Modification |
Summary
Protein Function
Ubiquitin-conjugating enzyme E2 that specifically acts with HECT-type and RBR family E3 ubiquitin-protein ligases. Does not function with most RING-containing E3 ubiquitin-protein ligases because it lacks intrinsic E3-independent reactivity with lysine: in contrast, it has activity with the RBR family E3 enzymes, such as PRKN and ARIH1, that function like function like RING-HECT hybrids. Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. In vitro catalyzes 'Lys-11'-linked polyubiquitination. Involved in the selective degradation of short-lived and abnormal proteins. Down-regulated during the S-phase it is involved in progression through the cell cycle. Regulates nuclear hormone receptors transcriptional activity. May play a role in myelopoiesis. (From Uniprot)
UBE2L3 expressed in 226 organ(s), highest expression level in C1 segment of cervical spinal cord.
The reaction of UBE2L3:
Cys Function & Property
Cys87 is the active site of UBE2N, which could form a glycyl thioester intermediate during the catalysis.
- Hydrophobic property:
- SASA：
- Cys87: 32.715 A^2
Protein Sequence
MAASRRLMKE LEEIRKCGMK NFRNIQVDEA NLLTWQGLIV PDNPPYDKGA
FRIEINFPAE YPFKPPKITF KTKIYHPNID EKGQVCLPVI SAENWKPATK
TDQVIQSLIA LVNDPQPEHP LRADLAEEYS KDRKKFCKNA EEFTKKYGEK
RPVD
Structural Information
- Known structures with covalent ligands:
- Unknown
- Protein structure:
Related Pathway
Experimental Evidence
- MALDI-TOF/MS, Tryptic Digest
Reference
- Strickson S, Campbell D G, Emmerich C H, et al. The anti-inflammatory drug BAY 11-7082 suppresses the MyD88-dependent signalling network by targeting the ubiquitin system[J]. Biochemical Journal, 2013, 451(3): 427-437. 23441730
